• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

维持性免疫抑制药物方案对肾移植结局的影响。

Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome.

作者信息

Opelz G

机构信息

Department of Transplantation Immunology, University of Heidelberg, Germany.

出版信息

Transplantation. 1994 Aug 27;58(4):443-6. doi: 10.1097/00007890-199408270-00009.

DOI:10.1097/00007890-199408270-00009
PMID:8073513
Abstract

Renal transplant recipients require long-term maintenance immunosuppression for prevention of graft rejection. To reduce harmful side effects, combinations of immunosuppressive drugs are used. The effect on long-term outcome of different drug regimen has not been established. Over 12,000 kidney recipients who initially received triple-drug immunosuppressive therapy (cyclosporine, steroids, and azathioprine) after transplantation were studied. Graft and patient survival rates were analyzed over a 5-year period in relation to the 1-year immunosuppressive regimen. Five-year graft survival was significantly higher in 1270 patients who were changed from triple-drug therapy to steroid-free maintenance with cyclosporine (with or without the addition of azathioprine) (87 +/- 1%) than in 8024 patients who remained on triple-drug therapy (76 +/- 1%, P < 0.0001), 2829 patients on cyclosporine and steroids (79 +/- 1%, P < 0.0001), and 830 patients on steroids and azathioprine (63 +/- 2%, P < 0.0001). Patient survival was also significantly higher in patients on steroid-free maintenance (P < 0.0001). Steroid-free patients received significantly higher doses of cyclosporine than patients on regimens containing steroids (P < 0.0001). The immunosuppressive maintenance protocols that are currently most widely used appear to give suboptimal results. We suggest that discontinuation of steroid therapy should be attempted in renal transplant recipients after they have experienced several months of stable graft function on triple-drug immunosuppression.

摘要

肾移植受者需要长期维持免疫抑制治疗以预防移植物排斥反应。为减少有害副作用,常联合使用免疫抑制药物。不同药物方案对长期预后的影响尚未明确。研究了12000多名肾移植受者,这些受者在移植后最初接受三联药物免疫抑制治疗(环孢素、类固醇和硫唑嘌呤)。在5年期间,根据1年的免疫抑制方案分析移植物和患者生存率。1270名从三联药物治疗改为使用环孢素(加或不加硫唑嘌呤)的无类固醇维持治疗的患者,其5年移植物生存率(87±1%)显著高于8024名继续接受三联药物治疗的患者(76±1%,P<0.0001)、2829名接受环孢素和类固醇治疗的患者(79±1%,P<0.0001)以及830名接受类固醇和硫唑嘌呤治疗的患者(63±2%,P<0.0001)。无类固醇维持治疗患者的患者生存率也显著更高(P<0.0001)。无类固醇患者接受的环孢素剂量显著高于含类固醇方案的患者(P<0.0001)。目前最广泛使用的免疫抑制维持方案似乎效果欠佳。我们建议,肾移植受者在三联药物免疫抑制治疗下经历数月移植物功能稳定后,应尝试停用类固醇治疗。

相似文献

1
Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome.维持性免疫抑制药物方案对肾移植结局的影响。
Transplantation. 1994 Aug 27;58(4):443-6. doi: 10.1097/00007890-199408270-00009.
2
Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. The Collaborative Transplant Study.环孢素、硫唑嘌呤和类固醇治疗对慢性移植物失功的影响。移植协作研究。
Kidney Int Suppl. 1995 Dec;52:S89-92.
3
Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.在初次单倍体相合活体供肾移植中,类固醇与硫唑嘌呤联合疗法对比类固醇、环孢素与硫唑嘌呤联合疗法:二十年经验
Iran J Kidney Dis. 2008 Jan;2(1):34-9.
4
Critical threshold of azathioprine dosage for maintenance immunosuppression in kidney graft recipients. Collaborative Transplant Study.
Transplantation. 2000 Mar 15;69(5):818-21. doi: 10.1097/00007890-200003150-00025.
5
A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe).一项比较三种基于环孢素的方案在尸体肾移植中应用效果的随机研究。意大利肾移植多中心研究组(SIMTRe)。
J Am Soc Nephrol. 1997 Apr;8(4):638-46. doi: 10.1681/ASN.V84638.
6
Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.台湾肾移植受者使用维持性免疫抑制药物的趋势:基于国民健康保险研究数据库的分析
Transplant Proc. 2012 Jan;44(1):190-2. doi: 10.1016/j.transproceed.2011.12.018.
7
Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.硫唑嘌呤与环孢素为基础的疗法用于原发性单倍体相合活体供肾移植的前瞻性随机研究:20年经验
Clin Exp Nephrol. 2007 Jun;11(2):151-155. doi: 10.1007/s10157-007-0467-6. Epub 2007 Jun 28.
8
Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.优化活体供肾移植受者的免疫抑制方案
Exp Clin Transplant. 2017 Feb;15(Suppl 1):16-23. doi: 10.6002/ect.mesot2016.L46.
9
Immunosuppression in live-related donor renal transplantation.活体亲属供肾移植中的免疫抑制
Natl Med J India. 2001 Mar-Apr;14(2):75-80.
10
Impact of the addition of maintenance steroids to a rapid steroid discontinuation immunosuppressive protocol following acute renal transplant rejection.在急性肾移植排斥反应后,在快速停用类固醇免疫抑制方案中添加维持性类固醇的影响。
Exp Clin Transplant. 2009 Dec;7(4):233-6.

引用本文的文献

1
Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells.精氨酸加压素(AVP)治疗可增加单核细胞衍生树突状细胞中抑制性免疫检查点分子的表达。
Immunol Res. 2024 Dec 11;73(1):6. doi: 10.1007/s12026-024-09579-1.
2
Long-term Prolonged-release Tacrolimus-based Immunosuppression in De Novo Kidney Transplant Recipients: 5-Y Prospective Follow-up of Patients in the ADVANCE Study.新发肾移植受者基于他克莫司的长期缓释免疫抑制治疗:ADVANCE研究中患者的5年前瞻性随访
Transplant Direct. 2023 Feb 8;9(3):e1432. doi: 10.1097/TXD.0000000000001432. eCollection 2023 Mar.
3
Recent Advances in Liposomal-Based Anti-Inflammatory Therapy.
基于脂质体的抗炎治疗的最新进展
Pharmaceutics. 2021 Jul 1;13(7):1004. doi: 10.3390/pharmaceutics13071004.
4
A Short History of Skin Grafting in Burns: From the Gold Standard of Autologous Skin Grafting to the Possibilities of Allogeneic Skin Grafting with Immunomodulatory Approaches.烧伤皮肤移植简史:从自体皮肤移植的金标准到免疫调节方法下异体皮肤移植的可能性
Medicina (Kaunas). 2021 Mar 2;57(3):225. doi: 10.3390/medicina57030225.
5
Outcomes Associated with Steroid Avoidance and Alemtuzumab among Kidney Transplant Recipients.肾移植受者中避免使用类固醇与阿仑单抗相关的结局
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):2030-8. doi: 10.2215/CJN.12161214. Epub 2015 Sep 4.
6
Steroids in kidney transplant patients.肾移植患者的类固醇治疗。
Semin Immunopathol. 2011 Mar;33(2):157-67. doi: 10.1007/s00281-011-0259-7. Epub 2011 Feb 18.
7
Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival.低剂量雷帕霉素联合环孢素 A 治疗对角膜同种异体移植物存活的影响。
Graefes Arch Clin Exp Ophthalmol. 2010 Oct;248(10):1447-56. doi: 10.1007/s00417-010-1420-z. Epub 2010 Jun 24.
8
Steroid withdrawal in pediatric and adult renal transplant recipients.儿童及成人肾移植受者的类固醇撤减
Pediatr Nephrol. 2005 Mar;20(3):409-17. doi: 10.1007/s00467-004-1765-9. Epub 2005 Jan 14.
9
Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.他克莫司。其在器官移植管理中的药理学及临床疗效的最新进展。
Drugs. 1997 Dec;54(6):925-75. doi: 10.2165/00003495-199754060-00009.
10
Prevention of transplant rejection: current treatment guidelines and future developments.移植排斥反应的预防:当前治疗指南与未来发展
Drugs. 1997 Oct;54(4):533-70. doi: 10.2165/00003495-199754040-00003.